Mentice AB (publ) (MNTC.ST)
SEK 19.0
(0.53%)
SEK 19.0
(0.53%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 14.1 Million SEK | -16.35% |
| 2022 | 16.86 Million SEK | 83.37% |
| 2021 | 9.19 Million SEK | 59.39% |
| 2020 | 5.76 Million SEK | -38.07% |
| 2019 | 9.31 Million SEK | 88.01% |
| 2018 | 4.95 Million SEK | -29.26% |
| 2017 | 7 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 16.81 Million SEK | 19.21% |
| 2024 Q2 | 13.64 Million SEK | -18.87% |
| 2023 Q1 | 15.22 Million SEK | -9.68% |
| 2023 Q3 | 12.98 Million SEK | -2.57% |
| 2023 FY | 14.1 Million SEK | -16.35% |
| 2023 Q4 | 14.1 Million SEK | 8.65% |
| 2023 Q2 | 13.32 Million SEK | -12.52% |
| 2022 Q2 | 10.13 Million SEK | 6.22% |
| 2022 FY | 16.86 Million SEK | 83.37% |
| 2022 Q1 | 9.53 Million SEK | 3.73% |
| 2022 Q4 | 16.86 Million SEK | 48.58% |
| 2022 Q3 | 11.34 Million SEK | 12.01% |
| 2021 Q1 | 6.05 Million SEK | 4.97% |
| 2021 Q4 | 9.19 Million SEK | 31.24% |
| 2021 FY | 9.19 Million SEK | 59.39% |
| 2021 Q3 | 7 Million SEK | 16.49% |
| 2021 Q2 | 6.01 Million SEK | -0.69% |
| 2020 Q1 | 8.8 Million SEK | -5.54% |
| 2020 FY | 5.76 Million SEK | -38.07% |
| 2020 Q4 | 5.76 Million SEK | 10.05% |
| 2020 Q3 | 5.24 Million SEK | -28.29% |
| 2020 Q2 | 7.31 Million SEK | -16.93% |
| 2019 Q3 | 5.5 Million SEK | 24.5% |
| 2019 Q2 | 4.42 Million SEK | -30.58% |
| 2019 Q1 | 6.36 Million SEK | 28.5% |
| 2019 FY | 9.31 Million SEK | 88.01% |
| 2019 Q4 | 9.31 Million SEK | 69.29% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | 4.95 Million SEK | -29.26% |
| 2018 Q4 | 4.95 Million SEK | 0.0% |
| 2017 FY | 7 Million SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | -106.229% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 88.363% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 88.363% |
| Arcoma AB | 28.02 Million SEK | 49.677% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 52.425% |
| BICO Group AB (publ) | 493.1 Million SEK | 97.14% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 77.397% |
| CellaVision AB (publ) | 126.03 Million SEK | 88.81% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | -130.646% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | -696.422% |
| C-Rad AB (publ) | 64.09 Million SEK | 77.997% |
| Duearity AB (publ) | 4.15 Million SEK | -239.12% |
| Dignitana AB (publ) | 7.41 Million SEK | -90.26% |
| Episurf Medical AB (publ) | 3.7 Million SEK | -281.189% |
| Getinge AB (publ) | 6.41 Billion SEK | 99.78% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 937.843% |
| Iconovo AB (publ) | -4.86 Million SEK | 390.086% |
| Integrum AB (publ) | 22.36 Million SEK | 36.929% |
| Luxbright AB (publ) | 8000.00 SEK | -176200.0% |
| OssDsign AB (publ) | 4.3 Million SEK | -227.695% |
| Paxman AB (publ) | 19.99 Million SEK | 29.476% |
| Promimic AB (publ) | 330 Thousand SEK | -4173.939% |
| Qlife Holding AB (publ) | 7.29 Million SEK | -93.417% |
| SciBase Holding AB (publ) | 11.91 Million SEK | -18.332% |
| ScandiDos AB (publ) | 22.69 Million SEK | 37.84% |
| Sectra AB (publ) | 36.59 Million SEK | 61.454% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 67.181% |
| Senzime AB (publ) | 20.34 Million SEK | 30.659% |
| SpectraCure AB (publ) | 1.00 SEK | -1410399900.0% |
| Stille AB | 66.55 Million SEK | 78.808% |
| Vitrolife AB (publ) | 413 Million SEK | 96.585% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 90.04% |